Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Patients With Potentially Operable, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

NCT01715142 is registered in ClinicalTrials.gov with Jean-Luc Van Laethem as lead sponsor.

NCT NCT01715142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01715142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Patients With Potentially Operable, Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Lead sponsor
Jean-Luc Van Laethem
Phase
Phase 1
Overall status
Completed
Start date
March 21, 2013
Completion date
April 30, 2017
Enrollment
23 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma locally advanced, pancreatic adenocarcinoma metastatic, pancreatic adenocarcinoma resectable